### Appendix 3B

# New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12, 04/03/13

04/03/13		
Name o	of entity	
BRAII	NCHIP HOLDINGS LTD	
ABN		
64 151	159 812	
We (t	he entity) give ASX the following info	rmation.
	1 - All issues ust complete the relevant sections (attach sheet	ts if there is not enough space).
1	<sup>+</sup> Class of <sup>+</sup> securities issued or to be issued	(a) Options to acquire fully paid ordinary shares (unquoted)
	issueu	(b) Class C Performance Rights (unquoted)
		(e) class of errormance ragins (anquotea)
2	Number of *securities issued or to be	(a) 1,500,000
	issued (if known) or maximum	(b) 500,000
	number which may be issued	

- Principal terms of the \*securities (e.g. if options, exercise price and expiry date; if partly paid \*securities, the amount outstanding and due dates for payment; if \*convertible securities, the conversion price and dates for conversion)
- (a) Options exercisable at \$0.23 per Option on or before 1 February 2021 issued to BrainChip employees/consultants under the Company's Long Term Incentive Plan approved by shareholders on 30 July 2015. 25% of the Options will vest and become exercisable on each anniversary of the Issue Date so long as the Participant is providing continuous service to the Company.
- Performance Rights Class C Performance **Rights** issued BrainChip to employees/consultants under the Company's Performance Rights approved by shareholders on 30 July 2015. Each Performance Right carries a right to one fully paid ordinary share, the Performance Rights will vest on the date the milestone relating to that Performance Right has been satisfied, no amount is payable upon the issue or vesting of the Performance Rights. The Performance Rights will automatically lapse on 10 September 2020 and the further terms set out in the Company's Notice of General Meeting announced on 30 June 2015.
- 4 Do the \*securities rank equally in all respects from the \*issue date with an existing \*class of quoted \*securities?

If the additional \*securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 5 Issue price or consideration

- (a) No, upon the exercise of the Options the fully paid ordinary shares issued will rank equally with the fully paid ordinary shares on issue.
- (b) No. Performance Rights are not quoted securities and do not rank equally with ordinary shares. Any ordinary share issued or transferred to the holder of a Performance Right upon vesting will rank equally from the date of allotment with other ordinary shares.
- (a) Nil, issued to a BrainChip employees/consultants under the Company's Long Term Incentive Plan approved by shareholders on 30 July 2015.
- (b) Nil, issued to the BrainChip issued to BrainChip employees/consultants under the Company's Performance Rights Plan approved by shareholders on 30 July 2015.

<sup>+</sup> See chapter 19 for defined terms.

6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	<ul> <li>(a) Issued to BrainChip employees/consultants under the Company's Long Term Incentive Plan approved by shareholders on 30 July 2015.</li> <li>(b) Issued to BrainChip employees/consultants under the Company's Performance Rights Plan approved by shareholders on 30 July 2015.</li> </ul>
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	No
	If Yes, complete sections 6b – 6h <i>in</i> relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A
6f	Number of *securities issued under an exception in rule 7.2	None
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A

6i	Calculate the entity's remaining issue
	capacity under rule 7.1 and rule 7.1A -
	complete Annexure 1 and release to
	ASX Market Announcements

N/A			

#### 7 +Issue dates

Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.

Cross reference: item 33 of Appendix 3B.

ı February 2016		

8 Number and \*class of all \*securities quoted on ASX (*including* the \*securities in section 2 if applicable)

Number	+Class
239,700,608 Ordinary fully paid shar	
İ	

<sup>+</sup> See chapter 19 for defined terms.

Number and \*class of all \*securities 9 not quoted on ASX (including the +securities in section 2 if applicable)

Number	+Class
431,174,644	Ordinary fully paid shares (restricted)
11,000,000	Options Exercisable at \$0.225 on or before 30 November 2018
10,550,000	Options Exercisable at \$0.24 on or before 21 December 2020
250,000	Options Exercisable at \$0.36 on or before 21 December 2020
1,500,000	Options Exercisable at \$0.23 on or before 1 February 2021
6,250,000	Options Exercisable at \$0.157 on or before 10 September 2019 (restricted)
13,500,000	Class A Performance Rights (restricted)
13,500,000	Class B Performance Rights (restricted)
49,000,000	Class C Performance Rights (46,500,000 restricted, 2,500,000 unrestricted)
46,500,000	Class D Performance Rights (restricted)

distribution policy) on the increased capital (interests)

10

Dividend policy (in the case of a trust, The Company has not formulated a dividend policy at this time.

#### Part 2 - Pro rata issue

11	Is security holder approval required?
12	Is the issue renounceable or non-renounceable?
13	Ratio in which the *securities will be offered
14	*Class of *securities to which the offer relates
15	<sup>+</sup> Record date to determine entitlements
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?
17	Policy for deciding entitlements in relation to fractions
18	Names of countries in which the entity has security holders who will not be sent new offer documents
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.
19	Closing date for receipt of acceptances or renunciations
20	Names of any underwriters
21	Amount of any underwriting fee or commission
22	Names of any brokers to the issue
23	Fee or commission payable to the broker to the issue

<sup>+</sup> See chapter 19 for defined terms.

24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	
25	If the issue is contingent on security holders' approval, the date of the meeting	
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	
28	Date rights trading will begin (if applicable)	
29	Date rights trading will end (if applicable)	
30	How do security holders sell their entitlements <i>in full</i> through a broker?	
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	
32	How do security holders dispose of their entitlements (except by sale through a broker)?	
33	<sup>+</sup> Issue date	

#### Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

	(tick	of *securities one)
(a)		<sup>+</sup> Securities described in Part 1
(b)		All other *securities  Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities
Entiti	es tha	t have ticked box 34(a)
Addit	ional	securities forming a new class of securities
Tick to	indicat	a year are providing the information or
docum		e you are providing the information or
		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders

5,001 - 10,000 10,001 - 100,000 100,001 and over

37

A copy of any trust deed for the additional \*securities

<sup>+</sup> See chapter 19 for defined terms.

#### Entities that have ticked box 34(b)

38	Number of *securities for which *quotation is sought		
39	*Class of *securities for which quotation is sought		
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?		
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment		
41	Reason for request for quotation now  Example: In the case of restricted securities, end		
	of restriction period		
	(if issued upon conversion of another *security, clearly identify that other *security)		
		Number	+Class
42	Number and *class of all *securities quoted on ASX (including the *securities in clause 38)		

#### **Quotation agreement**

- <sup>†</sup>Quotation of our additional <sup>†</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>†</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the \*securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before 'quotation of the 'securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here: Nerida Schmidt Date: 5 February 2016

(Director/Company secretary)

Print name: NERIDA SCHMIDT

== == == ==

<sup>+</sup> See chapter 19 for defined terms.

## Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

#### Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue		
Add the following:		
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period under an exception in rule 7.2		
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
<b>Subtract</b> the number of fully paid <sup>+</sup> ordinary securities cancelled during that 12 month period		
"A"		

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15		
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:		
• Under an exception in rule 7.2		
Under rule 7.1A		
• With security holder approval under rule 7.1 or rule 7.4		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"		
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15		
Note: number must be same as shown in Step 2		
Subtract "C"		
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"		
	[Note: this is the remaining placement capacity under rule 7.1]	

<sup>+</sup> See chapter 19 for defined terms.

#### Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"		
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A		
Notes:  This applies to equity securities – not just ordinary securities  Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed  Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained  It may be useful to set out issues of securities on different dates as separate line items		

<sup>+</sup> See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A	
"A" x 0.10	
Note: number must be same as shown in Step 2	
Subtract "E"	
Note: number must be same as shown in Step 3	
<b>Total</b> ["A" x 0.10] – "E"	
	Note: this is the remaining placement capacity under rule 7.1A

Appendix 3B Page 14 01/08/2012

<sup>+</sup> See chapter 19 for defined terms.